Misguided?
The guidelines have moved on to doctors' radar screens over the past decade or so, in line with an increased emphasis on using 'evidence-based' methods to treat patients. Many major professional bodies around the world, such as the American College of Physicians, now publish several guideline documents every year. The advice is based on the results of clinical trials, and tells doctors which drugs to prescribe and when.
In its survey, Nature studied more than 200 guidelines from around the world that were deposited with the US National Guideline Clearinghouse in 2004. Only 90 contained details about individual authors' conflicts of interest. Of those, just 31 were free of industry influence.
Half of those that gave individual details had at least one author with a conflicting advisory position in the pharmaceutical industry. More than a third of the panels included at least one member who gave seminars on behalf of a relevant drug company. And one in ten contained a member who owned stock in a company with products being considered.
The latter type of conflict is especially worrying, says Bruce Fye of the Mayo Clinic in Rochester, Minnesota, who raised the issue of guideline ethics during his presidency of the American College of Cardiology in 2002-3. Prescription practices promoted by guidelines can have a direct effect on drug sales and thus stock price. "Stock options should be viewed as unacceptable, " he says.
In one example uncovered by Nature, guidelines for the treatment of anaemia in HIVpositive patients were written by a working group selected by Paul Volberding, a leading AIDS researcher and physician, and vicechairman of the Department of Medicine at the University of California, San Francisco. Volberding convened the group at the request of Ortho Biotech, a pharmaceutical company based in Bridgewater, New Jersey. Ortho Biotech funded the group's meetings, and all six members, including Volberding, had been paid by the company for lecturing or consultancy jobs. The group's latest guidelines, published last year (P. Volberding et al. Clin. Infect. Dis. 38, 1454 -1463 2004) , recommend the use of epoetin alpha, a drug marketed by Ortho Biotech.
Slippery stats
Physicians' organizations say that one or two authors with a conflict of interest could not influence a panel containing tens of members. But assessing just how many authors have such conflicts is difficult. In the Nature survey, 35% of the 685 authors involved declared conflicting industry links (see graphic). Experts say that this is likely to be an underestimate, however, because it relies on authors' own declarations.
For example, the Center for Science in the Public Interest (CSPI), based in Washington DC, examined the disclosure statements on some randomly chosen blood-pressure guidelines published last year. Only one author declared a conflict of interest, but further checks by the CSPI revealed that four other authors had failed to disclose research funding from relevant drug companies.
The problem could be even worse in guidelines that don't contain conflict-of-interest declarations, warns Merrill Goozner, director of the CSPI's Integrity in Science project. "It is usually the journals and supplements that rely heavily on industry advertising that are least likely to have good disclosure policies. " The organizations that produce guidelines argue that industry links do not necessarily lead to biased advice. Some employ review panels to check prospective guidelinesalthough conflicts of interest are just as likely to occur in review panels. And authors insist that they are careful to avoid bias. "We realized this would be a concern and so looked very "It's not true that people can remain completely objective." 373-380; 2000) . "It's not true that people can remain completely objective, " says Peter Gøtzsche, director of the Nordic Cochrane Centre in Copenhagen, Denmark, which runs independent reviews of drug efficacy.
CONFLICTS OF INTEREST
Gøtzsche and others want guidelines to be prepared in ways that reduce the potential for bias. Some such schemes already exist. In Britain, for example, guidelines are provided by a government-funded body called the National Institute for Health and Clinical Excellence (NICE). Although some of the experts used by NICE have industry links, the institute itself is independent of industry and consults with other stakeholders, such as patients' groups.
Expert witnesses
In the United States an alternative process is being used for conditions where there is conflicting evidence as to the best treatment. Experts in a particular condition -those most likely to have relevant industry linksare used as witnesses, but the panel members themselves are chosen for their skills at examining medical data. "If you have a conflict of interest you can't be on the panel, " says Susan Rossi, deputy director of the Office of Medical Applications of Research at the National Institutes of Health, which runs the scheme.
But the bodies that produce guidelines maintain that there just aren't enough experts without conflicts of interest. Nathaniel Clark of the American Diabetes Association estimates that three-quarters of members eligible to write guidelines have industry links, and other organizations report a similar number.
The latest figures underline the urgency of breaking the deadlock. In 2002, Choudhry and colleagues found similar levels of conflicts of interest, but he says that physicians have since assumed that disclosing conflicts is all that is required to solve the problem. With drugcompany stock-holders still sitting on the panels that make prescription decisions, Choudhry warns: "We need a better way to deal with conflicts of interest. "
■

Rosie Taylor and Jim Giles
Get set for a revival of interest in Earth's wayward twin. The European Space Agency (ESA) plans to launch Venus Express next week -the first visit to the planet in more than a decade. The focus of the €220-million (US$265-million) mission will be the planet's thick atmosphere, which some think could host exotic life forms that use ultraviolet instead of visible light. Venus Express will begin its journey from Kazakhstan on a Soyuz-Fregat rocket; the month-long launch window opens on 26 October. ESA developed the mission -its first to Venus -in less than four years, after asking the science community for ideas on adapting its Mars Express spacecraft for another purpose.
The craft uses cameras and spectrometers adapted from Mars Express and Rosetta, an upcoming comet mission. These will build up a three-dimensional profile of Venus's carbon dioxide-rich atmosphere, which traps heat and drives temperatures on the surface to a searing 450 ᑻC. Grinspoon calls this a kind of "thought experiment", and does not claim there is evidence for life on Venus today. Nor does he believe that terrestrial microbes stowing away on Venus Express risk contaminating the planet. Current international guidelines for planetary protection require sterilization for Mars-bound spacecraft, but not for those headed for hot and acidic Venus.
Still, NASA has asked the US National Academy of Sciences, based in Washington DC, to revisit the subject of planetary protection for Venus. Thirty years have passed since it last looked at the question, says NASA planetary-protection officer John Rummel. At present, the agency is mulling over ideas for samplereturn missions to Venus, and the academy has recommended that a lander be sent to the planet in the next decade.
In the meantime, Japan plans to launch its Venus Climate Orbiter in 2008, and two Mercury-bound spacecraft -MESSENGER and BepiColombo -will study Venus during brief fly-bys. ■
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Express delivery to Venus
Europe's first mission to Venus is set for launch later this month.
